Ítem
Acceso Abierto

Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. The Pan-American Collaborative Retina Study Group at 24 Months

Mostrar el registro sencillo de la publicación
dc.creatorArevalo, J. Fernandospa
dc.creatorSanchez, Juan G.spa
dc.creatorWu, Lihtehspa
dc.creatorMaia, Mauriciospa
dc.creatorAlezzandrini, Arturo A.spa
dc.creatorBrito, Miguelspa
dc.creatorBonafonte, Sergiospa
dc.creatorLujan, Silviospa
dc.creatorDiaz-Llopis, Manuelspa
dc.creatorRestrepo, Nataliaspa
dc.creatorRodríguez, Francisco J.spa
dc.creatorUdaondo-Mirete, Patriciaspa
dc.creatorGroup, Pan-American Collaborative Retina Studyspa
dc.creator.OrganizationalPan-American Collaborative Retina Study Group (PACORES)
dc.date.accessioned2020-05-25T23:57:43Z
dc.date.available2020-05-25T23:57:43Z
dc.date.created2009spa
dc.description.abstractPurpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the 2 different doses of intravitreal bevacizumab (IVB) used is presented. Design: Retrospective, multicenter, interventional, comparative case series. Participants: The clinical records of 115 consecutive patients (139 eyes) with DDME at 11 centers from 8 countries were reviewed. Methods: Patients were treated with at least 1 intravitreal injection of 1.25 or 2.5 mg of bevacizumab. All patients were followed up for 24 months. Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at the baseline, 1-, 3-, 6-, 12-, and 24-month visits. Main Outcome Measures: Changes in BCVA and OCT results. Results: The mean age of the patients was 59.4±11.1 years. The mean number of IVB injections per eye was 5.8 (range, 1-15 injections). In the 1.25-mg group at 1 month, BCVA improved from 20/150 (0.88 logarithm of the minimum angle of resolution [logMAR] units) to 20/107, 0.76 logMAR units (P less than 0.0001). The mean BCVA at 24 months was 20/75 (0.57 logMAR units; P less than 0.0001). Similar BCVA changes were observed in the 2.5-mg group: at 1 month, BCVA improved from 20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units; P = 0.02). The mean BCVA at 24 months was 20/114 (0.76 logMAR units; P less than 0.0001). In the 1.25-mg group, the mean central macular thickness (CMT) decreased from 466.5±145.2 ?m at baseline to 332.2±129.6 ?m at 1 month and 286.6±81.5 ?m at 24 months (P less than 0.0001). Similar results were obtained in the 2.5-mg group. Conclusions: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in DDME at 24 months. The results show no evident difference between IVB at doses of 1.25 or 2.5 mg. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2009 American Academy of Ophthalmology.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.ophtha.2009.03.016
dc.identifier.issn15494713
dc.identifier.issn01616420
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22731
dc.language.isoengspa
dc.publisherElsevier Inc.spa
dc.relation.citationEndPage1497.e1
dc.relation.citationIssueNo. 8
dc.relation.citationStartPage1488
dc.relation.citationTitleOphthalmology
dc.relation.citationVolumeVol. 116
dc.relation.ispartofOphthalmology, ISSN:15494713, 01616420, Vol.116, No.8 (2009); pp. 1488-1497.e1spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-68049148355&doi=10.1016%2fj.ophtha.2009.03.016&partnerID=40&md5=97c687886c2854107925a35c255eda2aspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordArgentinaspa
dc.subject.keywordArticlespa
dc.subject.keywordBrazilspa
dc.subject.keywordCataractspa
dc.subject.keywordCerebrovascular accidentspa
dc.subject.keywordColombiaspa
dc.subject.keywordComparative studyspa
dc.subject.keywordControlled studyspa
dc.subject.keywordCosta ricaspa
dc.subject.keywordDiabetic macular edemaspa
dc.subject.keywordDiabetic retinopathyspa
dc.subject.keywordDrug dose comparisonspa
dc.subject.keywordEye examinationspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescence angiographyspa
dc.subject.keywordFollow upspa
dc.subject.keywordFunctional anatomyspa
dc.subject.keywordHeart infarctionspa
dc.subject.keywordHumanspa
dc.subject.keywordHypertensionspa
dc.subject.keywordIntervention studyspa
dc.subject.keywordIntraocular pressurespa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordMexicospa
dc.subject.keywordOphthalmoscopyspa
dc.subject.keywordOptical coherence tomographyspa
dc.subject.keywordPeruspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRetina detachmentspa
dc.subject.keywordRetina macula luteaspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordSide effectspa
dc.subject.keywordSpainspa
dc.subject.keywordThicknessspa
dc.subject.keywordUnited statesspa
dc.subject.keywordVenezuelaspa
dc.subject.keywordVisual acuityspa
dc.titlePrimary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. The Pan-American Collaborative Retina Study Group at 24 Monthsspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1-s2-0-S0161642009002802.pdf
Tamaño:
913.1 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos